Profound Medical Corp.
PROFNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for PROF. That does not mean none is planned.
Get an email about PROF's next catalysts
Track Profound Medical (PROF) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming, 1 past
PROF Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.19 | FQ end Sep/2026 | Call: tbd
Q3 2026 revenue of ~$9.8M, up 86% YoY; gross margin 78%; cash used in operating activities down 56% sequentially; new Cook Medical distribution agreement; CEO transition to Richard Fabian effective Jan 14, 2027.
Market Overview
Stock performance and key metrics
No drugs found in this phase.
Frequently asked questions
When is Profound Medical Corp.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Profound Medical Corp. (PROF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PROF biotech catalysts?→
Add PROF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Profound Medical Corp.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.